Extracorporeal Membrane Oxygenation (ECMO) as a Therapeutic Option in Severe Form of COVID-19: a Nationwide Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 761
- 试验地点
- 88
- 主要终点
- Hospital mortality
研究概览
简要总结
The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to report the results of the ECMO management of the most severe forms of COVID-19 through the first French ECMO registry.
详细描述
The main objective of this study is to evaluate the hospital survival of COVID-19 patients supported by venovenous or venoarterial ECMO in a multicenter registry.
The secondary objectives are to describe the characteristics of COVID-19 patients who have received ECMO support, to identify the risk factors associated with hospital mortality, to analyze the outcomes after ECMO weaning including survival at day 28 and day 90, and to analyze the utility of a circulatory support mobile unit in a severe pandemic
Inclusions are both prospective and retrospective in order to collect data over the whole pandemic
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All COVID-19 patients, adults or children,
- •Tested positive by RT-PCR for SARS-CoV2 (nasopharyngeal swabs, sputum, endotracheal aspiration, bronchoalveolar lavage or stool sample) and / or with a diagnosis made on chest CT findings,
- •Supported by venovenous or venoarterial ECMO
排除标准
- •Temporary legally protected Adults over a set period or waiting for protection supervision, guardianship
- •Patients or proxies who express their opposition to study participation
结局指标
主要结局
Hospital mortality
时间窗: up to 90 days
Hospital mortality
次要结局
- Mortality Day 90(Day 90)
- Ventilator-free days(Day 28)
- Mortality Day 28(Day 28)
- Intensive care unit-free days(Day 28)
- Hospital-free days(Day 28)